Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is a clinical-stage biotech company that has developed a proprietary Precision Endocrine Peptide (PEP) platform for peptide drug design and development. The company's lead asset, canvuparatide, has shown promising Phase 2 data in patients with hypoparathyroidism, and we believe it has potential for differentiation in terms of convenience, safety, and efficacy. With upcoming catalysts, including Phase 3 data, we have a positive outlook on the company's potential for regulatory approval and commercial success.

Bears say

MBX Biosciences is facing significant challenges in the market due to its high-risk, clinical stage status and limited product portfolio. While the company's PEP platform may offer some advantages, the product candidates are still in the early stages of development and may not be able to meet the high expectations set by analysts. Additionally, the long timeline for potential launch and peak sales, coupled with the limited market potential for MBX 4291, may make it a less attractive investment opportunity for investors.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.